Chronic Limb-Threatening Ischemia
FDA clears IVL catheter for treatment of below-the-knee PAD
Shockwave Medical announced the FDA clearance and full U.S. launch of its peripheral intravascular lithotripsy catheter designed to treat calcified femoropopliteal and below-the-knee peripheral artery disease.
FDA approves novel bioresorbable scaffold for treating chronic limb-threatening ischemia
Abbott announced the FDA has approved its novel below-the-knee, bioresorbable, drug-eluting scaffold for people with chronic limb-threatening ischemia.
Novel implant for below-the-knee treatment of CLTI gains breakthrough device designation
Elixir Medical announced it received breakthrough device designation FDA for its novel adaptive implant for the treatment of narrowed or blocked below-the-knee vessels in patients with chronic limb-threatening ischemia.
FDA grants breakthrough device designation for resorbable magnesium scaffold for CLTI
Biotronik announced it was granted breakthrough device designation from the FDA its below-the-knee resorbable magnesium scaffold for the treatment of chronic limb-threatening ischemia.
FDA grants device for treatment of chronic limb-threatening ischemia breakthrough status
Efemoral Medical announced the FDA granted breakthrough device status to its vascular scaffold system for treatment of de novo or restenotic lesions of the infrapopliteal arteries in patients with chronic limb-threatening ischemia.
What you may have missed from TCT 2023
Healio and Cardiology Today have aggregated news you may have missed from TCT 2023 in San Francisco.
LIFE-BTK trial: Bioresorbable scaffold did not disrupt wound healing in patients with CLTI
An everolimus-eluting bioresorbable scaffold did not affect wound healing compared with angioplasty in patients with chronic limb-threatening ischemia, according to new data from the LIFE-BTK trial.
Deep venous arterialization continues to benefit patients with severe CLTI at 12 months
Most patients with severe chronic limb-threatening ischemia treated with a transcatheter deep venous arterialization system achieved limb salvage at 12 months, according to new data from the PROMISE II trial.
Bioresorbable scaffold superior to angioplasty for treating chronic limb-threatening ischemia
SAN FRANCISCO — An everolimus-eluting bioresorbable scaffold was superior to angioplasty for the treatment of patients with chronic limb-threatening ischemia, according to the results of the LIFE-BTK trial presented at TCT 2023.
Transcatheter deep venous arterialization system for CLTI gains FDA approval
LimFlow announced that its transcatheter deep venous arterialization system for treatment of chronic limb-threatening ischemia was approved by the FDA.